Drugs / Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02047019 | Dec 2017 → Dec 2019 | essential hypertension | Bayer | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047019 ↗ |
| Known as | BAY98-7106 | “Fixed Dose combination BAY98-7106 (nifedipine plus candesartan)” NCT02047019 ↗ |
| Route | Oral | “Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily” NCT02047019 ↗ |